Skip to main content

Neuroendocrine Tumours

  1. In the case of extravasation of radioactive drugs used in peptide-receptor radionuclide therapy of neuroendocrine tumors, or in radionuclide therapy in general, rapid action is important to reduce or avoid com...

    Authors: Anne Kirstine Arveschoug, Anne Charlotte Bekker, Peter Iversen, Henrik Bluhme, Gerda Elisabeth Villadsen and Peter Frøhlich Staanum

    Citation: EJNMMI Research 2020 10:68

    Content type: Case report

    Published on:

  2. 68Ga-labelled peptides targeting somatostatin receptor 2 (SSTR2) have demonstrated encouraging results in managing patients with neuroendocrine tumours (NETs). In addition to metal chelation, bifunctional chelat....

    Authors: Yuxiao Xia, Chengrun Zeng, Yanhong Zhao, Xinyi Zhang, Zibo Li and Yue Chen

    Citation: EJNMMI Research 2020 10:36

    Content type: Original research

    Published on:

  3. Positron emission tomography (PET) imaging with 68Gallium labeled somatostatin analogues (68Ga-DOTA-SSA) plays a key role in neuroendocrine tumor management. The impact of patient size on PET image quality is not...

    Authors: Christina P. W. Cox, Marcel Segbers, Laura H. Graven, Tessa Brabander and Daniëlle M. E. van Assema

    Citation: EJNMMI Research 2020 10:27

    Content type: Original research

    Published on:

  4. [18F]AmBF3-TATE is a somatostatin agonist that selectively binds to somatostatin receptor subtype 2 (SSTR2). For clinical translation, pharmacokinetics, radiation dosimetry, and acute toxicity of [18F]AmBF3-TATE ...

    Authors: Joseph Lau, Jinhe Pan, Etienne Rousseau, Carlos F. Uribe, Sudhakara Reddy Seelam, Brent W. Sutherland, David M. Perrin, Kuo-Shyan Lin and François Bénard

    Citation: EJNMMI Research 2020 10:25

    Content type: Original research

    Published on: